secukinumab (Cosentyx)
Jump to navigation
Jump to search
Indications
- treatment of moderate-severe plaque psoriasis (FDA-approved Jan 2015)
- psoriatic arthritis[3][5]
- ankylosing spondylitis[4][5]
- hidradenitis suppurativa[6]
Dosage
- loading dose of 150-300 mg SQ[3] (psoriatic arthritis)
- 150-300 mg SQ for 4 weeks (5 doses), then every 4 weeks
* intravenous formulation FDA-approved
Adverse effects
- candidiasis (resolves with treatment)
- nasopharyngitis
- upper respiratory infections
- headache
- neutropenia (1%)
- can cause flares of inflammatory bowel disease[5]
Mechanism of action
- fully humanized IgG monoclonal antibody
- selectively binds to & inhibits interleukin-17A
More general terms
References
- ↑ Langley RG et al. Secukinumab in plaque psoriasis - Results of two phase three trials. N Engl J Med 2014 Jul 9 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25007392 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1314258
- ↑ Brooks M Medscape: FDA Clears Secukinumab (Cosentyx) for Plaque Psoriasis. http://www.medscape.com/viewarticle/838491
FDA News Release. January 21, 2015 FDA approves new psoriasis drug Cosentyx http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htm - ↑ 3.0 3.1 3.2 Kuznar W PsA Structural Damage Inhibited with Secukinumab - Loading dose appears to improve outcomes, researchers say. MedPage Today. Nov 9, 2017 https://www.medpagetoday.com/meetingcoverage/acr/69156
Mease PJ et al Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study American College of Rheumatology (ACR) 2017; Abstract 17L. - ↑ 4.0 4.1 Pavelka K, Kivitz A, Dokoupilova E et al Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017 Dec 22;19(1):285. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29273067 Free PMC Article
- ↑ 5.0 5.1 5.2 5.3 Medical Knowledge Self Assessment Program (MKSAP) 18, 19 American College of Physicians, Philadelphia 2018, 2022
- ↑ 6.0 6.1 Novartis. Oct 23, 2023 FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade. https://www.novartis.com/us-en/news/media-releases/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade